CASI Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . CASI Pharmaceuticals
CASI Stock  USD 0.92  0.02  2.59%   
CASI Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing CASI Pharmaceuticals' valuation are provided below:
Gross Profit
9.6 M
Profit Margin
(1.84)
Market Capitalization
15.3 M
Enterprise Value Revenue
1.2856
Revenue
26.8 M
We have found one hundred twenty available fundamental signals for CASI Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of CASI Pharmaceuticals prevailing fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 107.3 M. Enterprise Value is estimated to decrease to about 89.9 M

CASI Pharmaceuticals Total Revenue

34.46 Million

Check CASI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CASI Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 795.3 K, Selling General Administrative of 28.5 M or Other Operating Expenses of 82.3 M, as well as many indicators such as Price To Sales Ratio of 1.66, Dividend Yield of 0.0092 or PTB Ratio of 28.32. CASI financial statements analysis is a perfect complement when working with CASI Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with CASI Stock
Check out the analysis of CASI Pharmaceuticals Correlation against competitors.
For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.

CASI Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding18.5 M17.6 M8.6 M
Slightly volatile
Total Assets49.2 M61.7 M55.1 M
Slightly volatile
Total Current Liabilities44 M41.9 M11.8 M
Slightly volatile
Property Plant And Equipment Net13.7 M13.1 M6.4 M
Slightly volatile
Accounts Payable2.7 M2.5 M2.1 M
Slightly volatile
Cash27.4 M15.5 M27.4 M
Slightly volatile
Non Current Assets Total9.9 M16 M16.1 M
Slightly volatile
Cash And Short Term Investments32.1 M18.5 M30.2 M
Slightly volatile
Common Stock Total Equity1.7 M1.6 M867 K
Slightly volatile
Liabilities And Stockholders Equity49.2 M61.7 M55.1 M
Slightly volatile
Other Stockholder Equity849.7 M809.3 M545.1 M
Slightly volatile
Total Liabilities62.6 M59.6 M21.3 M
Slightly volatile
Property Plant And Equipment Gross20.6 M19.6 M7.4 M
Slightly volatile
Total Current Assets39.3 M45.5 M39 M
Slightly volatile
Common Stock2.2 K2.3 K426.6 K
Very volatile
Short and Long Term Debt Total26.7 M25.5 M7.2 M
Slightly volatile
Other Current Liabilities14.1 M13.4 M4.3 M
Slightly volatile
Net Receivables18.5 M17.6 M5.6 M
Slightly volatile
Non Current Liabilities Total18.6 M17.7 M11.6 M
Slightly volatile
Other Current Assets2.3 M2.6 M2.9 M
Pretty Stable
Short Term Debt23.7 M22.5 M5.2 M
Slightly volatile
Other Assets215.2 K226.6 K2.5 M
Pretty Stable
Property Plant Equipment26.6 M25.3 M9.4 M
Slightly volatile
Current Deferred Revenue1.7 M2.8 M1.7 M
Slightly volatile
Other Liabilities20.8 M19.8 M9.8 M
Slightly volatile
Capital Surpluse571.4 M799 M563 M
Slightly volatile
Long Term Debt Total1.6 M1.7 M1.5 M
Slightly volatile
Short and Long Term Debt22.2 M21.1 M7.8 M
Slightly volatile
Net Invested Capital17.3 M18.2 M47.9 M
Very volatile
Net Working Capital2.7 M2.8 M39.7 M
Slightly volatile
Capital Stock1.7 K1.8 K718.1 K
Slightly volatile
Capital Lease Obligations2.5 M4.3 M2.4 M
Slightly volatile
Long Term Investments1.5 M1.5 M13.2 M
Slightly volatile

CASI Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative28.5 M27.1 M14.1 M
Slightly volatile
Other Operating Expenses82.3 M78.4 M36.4 M
Slightly volatile
Total Operating Expenses61.3 M58.4 M29.7 M
Slightly volatile
Depreciation And Amortization2.8 M2.7 M1.3 M
Slightly volatile
Research Development10.7 M8 M7.4 M
Slightly volatile
Non Recurring7.2 M5.9 M9 M
Slightly volatile
Interest Income460.2 K619.9 K325.5 K
Slightly volatile
Reconciled Depreciation2.4 M2.7 M1.4 M
Slightly volatile
Selling And Marketing Expenses13.6 M20.5 M8 M
Slightly volatile

CASI Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow23.2 M15.4 M31.5 M
Pretty Stable
Depreciation2.8 M2.7 M1.3 M
Slightly volatile
Capital Expenditures262.2 K276 K4.8 M
Pretty Stable
End Period Cash Flow30.4 M15.5 M32.5 M
Very volatile
Stock Based Compensation1.4 M1.5 M3.4 M
Slightly volatile
Change To Netincome9.3 M9 M7.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.661.75319
Slightly volatile
Dividend Yield0.00920.01490.0089
Slightly volatile
Days Sales Outstanding339226265
Slightly volatile
Average Payables751.5 K791 K796.7 K
Pretty Stable
Stock Based Compensation To Revenue0.03910.041213.3551
Slightly volatile
Capex To Depreciation0.0880.09274.4773
Pretty Stable
Inventory Turnover4.273.814.8496
Slightly volatile
Days Of Inventory On Hand14499.21118
Slightly volatile
Payables Turnover6.045.752.7446
Slightly volatile
Sales General And Administrative To Revenue0.710.7425.7118
Slightly volatile
Research And Ddevelopement To Revenue0.270.2822.1669
Slightly volatile
Capex To Revenue0.00720.00763.2819
Slightly volatile
Cash Per Share1.151.213.7148
Very volatile
Days Payables Outstanding62.4465.729.5 K
Slightly volatile
Income Quality0.870.860.6647
Pretty Stable
Intangibles To Total Assets0.00480.00510.1116
Slightly volatile
Current Ratio0.930.988.672
Slightly volatile
Receivables Turnover3.672.142.7955
Slightly volatile
Capex Per Share0.01710.0180.5165
Very volatile
Average Receivables13 K13.6 K212.5 K
Slightly volatile
Revenue Per Share2.032.141.1277
Slightly volatile
Interest Debt Per Share1.641.731.1902
Pretty Stable
Debt To Assets0.390.370.1303
Slightly volatile
Operating Cycle383352333
Pretty Stable
Days Of Payables Outstanding62.4465.729.5 K
Slightly volatile
Quick Ratio0.810.858.5153
Slightly volatile
Cash Ratio0.320.337.5605
Slightly volatile
Days Of Inventory Outstanding14499.21118
Slightly volatile
Days Of Sales Outstanding336226221
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.90.911.197
Very volatile
Fixed Asset Turnover2.152.266.4531
Slightly volatile
Debt Ratio0.390.370.1303
Slightly volatile
Price Sales Ratio1.661.75319
Slightly volatile
Asset Turnover0.50.480.218
Slightly volatile

CASI Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap107.3 M110 M50.5 M
Slightly volatile

CASI Fundamental Market Drivers

CASI Upcoming Events

24th of April 2024
Upcoming Quarterly Report
View
15th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
24th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About CASI Pharmaceuticals Financial Statements

Investors use fundamental indicators, such as CASI Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although CASI Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue2.8 M1.7 M
Total Revenue32.8 M34.5 M
Cost Of Revenue15.7 M10.1 M
Stock Based Compensation To Revenue 0.04  0.04 
Sales General And Administrative To Revenue 0.74  0.71 
Research And Ddevelopement To Revenue 0.28  0.27 
Capex To Revenue 0.01  0.01 
Revenue Per Share 2.14  2.03 
Ebit Per Revenue(1.25)(1.19)

Currently Active Assets on Macroaxis

FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
CSANCosan SA ADR
RKTRocket Companies
When determining whether CASI Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CASI Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Casi Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Casi Pharmaceuticals Stock:
How To Invest In CASI
Details
Is CASI Stock a good investment?
Details
What is CASI Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of CASI Pharmaceuticals Correlation against competitors.
For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is there potential for Biotechnology market expansion? Will CASI introduce new products? Factors like these will boost the valuation of CASI Pharmaceuticals. Projected growth potential of CASI fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.02)
Revenue Per Share
1.622
Quarterly Revenue Growth
(0.60)
Return On Assets
(0.62)
Return On Equity
(10.95)
Investors evaluate CASI Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating CASI Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause CASI Pharmaceuticals' market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between CASI Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CASI Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, CASI Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY